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Background
An unprecedented effort from public and private inter-
national health agencies has been made to address the
urgent issue of malaria in pregnancy.
The selection of antimalarial drug therapy during
pregnancy currently depends upon the severity of the
disease, gestational age (stage of fetal development) and
patterns of drug resistance in the area. To combat
multi-drug resistance the WHO recommends include
the use of Artemisinin-based combination therapies.
To assist in policy formulation of arteminisin drug
combination therapy during pregnancy, artemisinin-deri-
vatives are currently undergoing preÂ¬clinical risk:bene-
fit assessments [1]. Recent animal trials have indicated
that arteminisins during pregnancy result in fetal
morbidity, low birthweight, cardiac and skeletal birth
defects [2].
Currently validated preclinical teratogenicity/embryo-
lethality drug screenÂ¬ing includes whole embryo
culture (WEC), Micromass (MM) limb bud and embryo-
nic stem cell (ESC) culture together with in vivo studies
to assess embryonic development [3,4].
However while in vivo screening assays to gestational
day (GD) 13+ enable unambiguous assessment of arte-
misinin-associated embryotoxicity, standard in vitro
48hr WEC studies from 9-11 GD end before the terato-
genic effects on vulnerable organ systems impacted by
the drug can be evaluated. To address this problem, the
WEC experiment is extended to 72 hours: after vascular
and limb bud development.
Materials and methods
For in vivo and in vitro studies timed-mated Sprague
Dawley female rats were administered with artesunate at
9 and 10GD (organogenesis). Validated total morpholo-
gical scoring systems are used to quantify development
of the heart, brain, mandibular and maxillary processes,
skeletal formation and otic and optic development [2].
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Figure 1 In vivo Control (L) and Artesunate-treated (17mg/kg) gestation day 12.
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lysis and de novo blood vessel formation of blood vessels
in the yolk-sac was also assessed.
Results
Extended (72 hours from gestational day 9-12) whole
embryo culture times clearly showed artesunate (an
artemisinin-derivative) to have dose-dependent effects
with total morphological scores increasing as dose was
reduced. Unequivocal effects were upon embryonic vas-
cularisation, fore-limb bud development, morphological
scores and 50% reduced fetal weight were clearly
demonstrated that would not have been seen after 48
hours of culture.
Analogous effects were confirmed in the in vivo
experiments at 17mg/kg (Fig 1).The earliest effects were
observed in yolk-sac size and vascularisation showing
50% reduction in fetal weight, 20% reduction in head
size and severely reduced vascular development at
13GD. There was also a 40% reduction in numbers of
nucleated erythroid progenitors. Figure 2.
Conclusions
These studies seek improve harmonization between the
current in vitro developmental toxicity assays and in
vivo assays for use in preclinical drug testing. The
results indicate that for compounds with teratogenic
potential specifically on skeletal and cardiac develop-
ment, 72hr whole embryo culture assay is a prerequisite
for valid in vitro assessment and to enable more relevant
equivalence with in vivo data.
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Figure 2 In vitro Control (L) and Artesunate-treated (0.5μg/mL) gestation day 12WECs at 72hr.
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